SynthesisAIDS research and therapy2025
Attrition rate of antiretroviral therapy and its influencing factors among Chinese people living with HIV/AIDS: a meta-analysis and system review.
Synthesis in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Characteristics, Healthcare Utilization, and Treatment Patterns Among People Living with HIV by Antiretroviral Therapy Use in the USA, 2021-2024.Infectious diseases and therapy · 2026Article
- Spatiotemporal heterogeneity and socioeconomic determinants of syphilis incidence in Xining, Northwest China: a geospatial analysis.BMC infectious diseases · 2026Article
- Effect of rapid antiretroviral therapy initiation on loss to follow-up, virologic failure, and immunologic failure among people living with HIV under the treat-all policy in China: a retrospective cohort study (2016-2023).Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo systematically evaluate the attrition rate of PWH undergoing ART and its influencing factors.
methodsWe systematically searched Embase, PubMed, Web of Science, The Cochrane Library, VIP, WanFang, CNKI, and the Chinese Biomedical Literature Database for studies on the attrition rate and/or influencing factors of ART in PWH. The search period covered from database inception to January 2025. Two researchers independently screened the literature, extracted data, and appraised the quality of the included studies. Data analyses were performed using RevMan 5.3 and Stata 16.0 software.
resultsA total of 19 studies were ultimately included, of which 11 were cohort studies, 4 were case-control studies, and 4 were cross-sectional studies. The meta-analysis showed that the attrition rate among PWH receiving ART was 4.0 per 100 person-years (95% CI: 2.0-5.0 per 100 person-years). Factors identified as influencing attrition among PWH included age(OR = 1.51, 95%CI:1.46,1.64), male gender(OR = 1.30, 95%CI:1.17,1.44), unmarried or living alone(OR = 1.43, 95%CI:1.30,1.59), alcohol consumption(OR = 8.48, 95%CI:1.33,53.74), infection via intravenous drug use(OR = 2.15, 95%CI:1.89,2.46), initial treatment regimen including protease inhibitors (PI) (OR = 1.58, 95%CI:1.34,1.86), baseline CD4⁺ T lymphocyte count > 350/µL(OR = 1.84, 95%CI:1.11,3.05), adverse drug reactions(OR = 1.71, 95%CI:1.26,2.34), inconvenient access to medication(OR = 5.38, 95%CI:1.79,16.18), low family support(OR = 4.81, 95%CI:1.86,12.44), passive acceptance of treatment(OR = 16.04, 95%CI:1.72,149.42), interval from diagnosis to ART initiation > 1 year(OR = 1.20, 95%CI:1.10,1.53), and ART initiation year in 2016 or later(OR = 1.57, 95%CI:1.28,1.93). (P < 0.05). For some factors(alcohol consumption, inconvenient access to medication, low family support, passive acceptance of treatment), the small number of included studies and/or substantial heterogeneity limits the certainty of the evidence and the stability of the findings; therefore, they should be interpreted with caution.
conclusionOur meta-analysis indicates that ART attrition among PWH in China is relatively high and influenced by multiple factors. Accelerating ART initiation, optimizing medication access and adverse-event management, and strengthening social and family support may reduce attrition and improve treatment outcomes. Trial registration This study has been registered in PROSPERO under the registration number CRD420251023033.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.